Full-Time

Post Market Senior Quality Engineer

Posted on 5/16/2025

Insulet Corporation

Insulet Corporation

1,001-5,000 employees

Develops tubeless insulin delivery systems

Compensation Overview

$68.7k - $103k/yr

+ No Bonus + No Equity + No Benefits

Senior

Acton, MA, USA

Requires on-site work from an Insulet office at least 1x/week; may work remotely other days.

Category
QA & Testing
Quality Assurance
Required Skills
Risk Management
Requirements
  • BS degree in engineering, a technical or scientific discipline; and/or equivalent combination of education and experience.
  • 3 - 5 years’ experience in a regulated environment.
Responsibilities
  • Reviews, revises and supports Risk Management activities to Quality System Regulation, ISO 13485 and ISO14971.
  • Provide guidance as needed to assure country specific compliance to the laws and regulations of the targeted market for distribution.
  • Apply sound, systematic problem solving methodologies identifying, prioritizing, communicating and driving resolution of quality issues.
  • Ability to lead investigations supporting CAPAs and other areas of the Quality System.
Desired Qualifications
  • Experience with QSR Part 820, ISO 13485 and ISO 14971.
  • Experience with methods and standards for the design, verification, and validation of medical device products.
  • Experience with statistical methods (e.g. statistical process control, sampling plans, gauge R&R, and design of experiments).
  • Experience with word processing, spreadsheet, database programs.
  • Master’s degree in engineering or technical or scientific discipline preferred.
  • Effective verbal and written communication skills.
  • Effective collaboration and communication with individuals at multiple levels in an organization.
  • Ability to organize and judge priorities.
  • Ability to generate and maintain accurate records.
  • Ability to follow up with task owners to close out open items.
  • Strong problem solving / root cause analysis skills.
  • Good verbal (including presentation) and written communication skills, especially technical report writing.

Insulet Corporation develops medical devices aimed at simplifying life for people with diabetes. Their main product, the Omnipod Insulin Management System, is a tubeless device that delivers insulin continuously for up to three days without needles. The Omnipod 5 Automated Insulin Delivery System integrates with a continuous glucose monitor, allowing users to manage blood sugar without multiple injections or fingersticks. Insulet differentiates itself by providing a convenient and user-friendly solution for insulin delivery, with the goal of enhancing the quality of life for individuals with diabetes.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for advanced diabetes solutions expands Insulet's market opportunities.
  • Omnipod 5's European expansion increases Insulet's international market presence.
  • Advancements in sensor technology enhance the reliability of Insulet's Omnipod system.

What critics are saying

  • Leadership transition to Ashley McEvoy may lead to strategic instability.
  • Increased competition from DexCom and Tandem Diabetes Care challenges Insulet's market share.
  • Potential financial strain from $450M senior notes offering could impact cash flow.

What makes Insulet Corporation unique

  • Insulet's Omnipod 5 integrates with Dexcom G7 CGM, enhancing diabetes management.
  • The RADIANT trial showcases Insulet's innovation in transitioning from daily injections to Omnipod.
  • Insulet's $452M trade secret victory strengthens its competitive position in insulin pump technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
RTTNews
Apr 28th, 2025
Insulet CEO Jim Hollingshead Resigns, Ashley McEvoy To Succeed; Raises Q1 Guidance

Insulet Corp. (PODD), a medical device company, on Monday announced that Chief Executive Officer Jim Hollingshead has resigned from the Board of Directors.

MD+DI
Apr 28th, 2025
Insulet Names Ex-J&J MedTech Chief Ashley McEvoy as CEO

Ashley McEvoy has been tapped to be president and CEO of Insulet.

Financial Modeling Prep
Mar 28th, 2025
Insulet Corporation's Financial Efficiency in the Medical Device Industry

Insulet competes with companies like DexCom, Tandem Diabetes Care, and Masimo Corporation in the diabetes care market.

Stock Titan
Mar 18th, 2025
Insulet Secures $450M Through Senior Notes Offering: Key Details on Strategic Debt Refinancing

Insulet raises $444.4M through senior notes to refinance existing convertible debt. Strategic move positions medical device maker for future growth while optimizing capital structure.

Stock Titan
Mar 18th, 2025
From Injections to Innovation - Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod(R) 5 in Adults and Children with Type 1 Diabetes

Insulet (NASDAQ: PODD) will present results from its multinational RADIANT trial at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2025.